drugset / Trial / NCT06122870

Summary

Gastrointestinal infections cause significant morbidity in the form of acute diarrheal illness in the United States (US) and among travelers to low- and middle-income countries (LMICs). One approach is to use passive protection (antibodies) to prevent infection. The purpose of this study are to assess the safety and tolerability of serum-derived bovine immunoglobulins in healthy adult subjects when orally administered and to estimate protective efficacy of those preparations against moderate-severe diarrhea upon challenge with Campylobacter C. jejuni strain CG8421.

Timeline

Start
2023-12-04
Primary completion
2024-06-04
Completion
2025-06-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CampETEC HBC Protein / enzyme biologic — Oral

Indications

No indication recorded.